Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors. (Q38068345)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23250648%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

review article

1 reference

title

Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23250648%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

main subject

arterial hypertension

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23250648%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Robert M. Tulloh

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23250648%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Andrew James Wardle

series ordinal

1

1 reference

28 August 2017

Robert M R Tulloh

series ordinal

2

1 reference

28 August 2017

publication date

19 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23250648%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23250648%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23250648%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23250648%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

213-219

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23250648%20AND%20SRC:MED&resulttype=core&format=json

Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Diagnosis and assessment of pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Neonatal persistent pulmonary hypertension treated with milrinone: four case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Clinical features of paediatric pulmonary hypertension: a registry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Sildenafil as a treatment for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Tadalafil therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Management of pulmonary hypertension in Down syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Childhood idiopathic pulmonary arterial hypertension: a national cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Updated clinical classification of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Sildenafil for pulmonary hypertension: dose-dependent improvement in exercise performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Inhibition of cGMP phosphodiesterase 5 suppresses matrix metalloproteinase-2 production in pulmonary artery smooth muscles cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Initial experience with tadalafil in pediatric pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-012-0598-8

Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

12 December 2020

Observations on peripheral microcirculation in young hypertensive patients

1 reference

12 December 2020

Sildenafil in pulmonary hypertension

1 reference

12 December 2020

Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children

1 reference

12 December 2020

10-Year Analysis of Adverse Event Reports to the Food and Drug Administration for Phosphodiesterase Type-5 Inhibitors

1 reference

12 December 2020